Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-05 00:05 | 2025-12-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $39.14 | 1,652 | $64,659 | 66,562 | -2.4% |
| 2025-09-03 23:06 | 2025-09-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $35.77 | 10,000 | $357,700 | 66,363 | -13.1% |
| 2025-06-04 23:05 | 2025-06-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $40.09 | 10,000 | $400,900 | 66,237 | -13.1% |
| 2025-03-06 00:05 | 2025-03-03 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $49.53 | 10,000 | $495,300 | 66,101 | -13.1% |
| 2024-12-04 00:05 | 2024-12-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $58.72 | 10,000 | $587,200 | 58,371 | -14.6% |
| 2024-09-05 23:05 | 2024-09-03 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $49.83 | 10,000 | $498,300 | 58,229 | -14.7% |
| 2024-05-21 23:07 | 2024-05-20 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $49.99 | 10,000 | $499,900 | 58,116 | -14.7% |
| 2023-11-23 00:05 | 2023-11-20 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $36.40 | 5,000 | $182,000 | 53,007 | -8.6% |
| 2022-03-04 00:06 | 2022-03-01 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $41.43 | 16,738 | $693,430 | 49,176 | -25.4% |
| 2021-12-23 02:54 | 2021-12-20 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $40.11 | 15,881 | $636,930 | 43,547 | -26.7% |
| 2021-07-02 23:20 | 2021-06-30 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $57.14 | 134 | $7,657 | 39,319 | -0.3% |
| 2021-03-31 23:17 | 2021-03-30 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $51.40 | 17,924 | $921,270 | 38,480 | -31.8% |
| 2020-12-24 00:11 | 2020-12-21 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $26.54 | 24,235 | $643,158 | 23,360 | -50.9% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.